Heart Failure and MRAs: Diving Deep Into the Pivotal FINEARTS-HF Trial
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Heart Failure and MRAs: Diving Deep Into the Pivotal FINEARTS-HF Trial
-
Narrated by:
-
By:
About this listen
In this podcast, Ty J. Gluckman, MD, MHA, discusses the pivotal phase III FINEARTS-HF trial and how the treatment landscape is evolving for patients with heart failure (HF) with mildly reduced or preserved ejection fraction, including:
- The emerging role of mineralocorticoid receptor antagonists in HF care
- Finerenone’s efficacy in reducing composite cardiovascular death and worsening HF events
- Why safety must be monitored, especially considering hyperkalemia risk
- Where HF guideline recommendations lack compared with the current evidence
Presenter
Ty J. Gluckman, MD, MHA
Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence Health System
Portland, Oregon
Program page:
https://bit.ly/448XcH0
No reviews yet